MediciNova, Inc. announced topline results of its Phase 2 clinical trial (MN-001-NATG-202) evaluating MN-001 (tipelukast) in patients with nonalcoholic fatty liver disease (NAFLD) and ...

This video delves into the subtle, early physical changes that could signal the onset of ALS (amyotrophic lateral sclerosis).

Researchers developed a nanopore sequencing pipeline that may improve genetic diagnosis of repeat expansion disorders, ...

Biotechs developing therapeutics to treat rare diseases include two that received FDA approvals this year for drugs to treat ...

Shionogi's acquisition of IntraBio would expand its rare disease portfolio following the recent acquisition of ALS drug, Radicava.

Shionogi& Co (TYO:4507) has agreed to acquire Austin, Texas-based drugmaker IntraBio for an upfront payment of $2 billion, ...

Shionogi’s IntraBio acquisition brings Aqneursa, a drug approved for treating two rare neurological disorders and the potential to expand to additional indications, both rare and common. It’s Shionogi ...

Shionogi will acquire IntraBio for $2 billion upfront, adding AQNEURSA for rare neurological diseases. See what the deal means for its portfolio. Read more.

The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") ...

Isao Teshirogi, Shionogi's chief executive. Shionogi has reached a $2 billion agreement to buy Anglo-US biotech IntraBio and ...

Just weeks after IntraBio secured a label expansion for its lead asset Aqneursa, Japanese drugmaker Shionogi is moving in to ...